A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
A federal judge has ordered Johnson & Johnson’s Janssen unit to pay $1.64 billion for illegally promoting HIV drugs Prezista ...
Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a ...
Janssen Products LP must pay over $1.6 billion in a False Claims Act suit for improperly billing the US government for HIV ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results